Baird Capital Portfolio Company GreenLight Biosciences Goes Public
This week, Baird Capital portfolio company GreenLight Biosciences (GreenLight) officially started trading on Nasdaq as a public company (NASDAQ: GRNA / GRNA.WS). This event follows last year's announcement of this intention through a business combination with Environmental Impact Acquisition Corporation (NASDAQ: ENVI), a publicly-traded special purpose acquisition company.
"Today an exciting new chapter begins as we become a publicly listed company and public-benefit corporation," said GreenLight CEO Andrey Zarur. "We are thrilled to accelerate commercialization by attracting the talent, investing in the tools, and scaling our manufacturing infrastructure to continue developing our platform for design, development, and production of unprecedented new applications for RNA."
Baird Capital initially invested in GreenLight in 2019. GreenLight harnesses the power of biology to develop RNA-based solutions for some of humanity's most significant challenges in human health through mRNA vaccines and therapeutics and in food production through RNA crop-protection products. The company's breakthrough cell-free RNA manufacturing platform, protected by numerous patents, allows for cost-effective and scalable RNA production.